Department of Neurology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, Faculty of Health Sciences, Odense, Denmark; Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.
Department of Neurology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, Faculty of Health Sciences, Odense, Denmark.
J Am Acad Dermatol. 2018 Apr;78(4):673-681.e9. doi: 10.1016/j.jaad.2017.11.042. Epub 2017 Dec 4.
Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer.
To examine the association between hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
From the Danish Cancer Registry, we identified patients (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with hydrochlorothiazide use.
High use of hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We found clear dose-response relationships between hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1.54 (95% CI, 1.38-1.71) and 7.38 (95% CI, 6.32-8.60) for BCC and SCC, respectively. Use of other diuretics and antihypertensives was not associated with NMSC.
No data on sun exposure were available.
Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC.
氢氯噻嗪是美国和西欧最常用的利尿剂和降压药之一，具有光敏性，先前与唇癌有关。
研究氢氯噻嗪的使用与基底细胞癌（BCC）和鳞状细胞癌（SCC）风险之间的关系。
我们从丹麦癌症登记处确定了 2004-2012 年间患有非黑色素瘤皮肤癌（NMSC）的患者（病例）。通过年龄和性别以 1:20 的比例匹配对照。通过丹麦处方登记处评估 1995-2012 年期间氢氯噻嗪的累积使用量。使用条件逻辑回归，我们计算了与氢氯噻嗪使用相关的 BCC 和 SCC 的比值比（OR）。
高剂量氢氯噻嗪（≥50,000mg）与 BCC 的 OR 为 1.29（95%置信区间 [CI]，1.23-1.35），与 SCC 的 OR 为 3.98（95% CI，3.68-4.31）。我们发现氢氯噻嗪的使用与 BCC 和 SCC 之间存在明显的剂量反应关系；累积剂量最高的类别（≥200,000mg 的 HCTZ）的 OR 分别为 1.54（95% CI，1.38-1.71）和 7.38（95% CI，6.32-8.60）。使用其他利尿剂和降压药与 NMSC 无关。
没有关于阳光暴露的数据。
氢氯噻嗪的使用与 NMSC 的风险显著增加有关，尤其是 SCC。
